NASDAQ: FPRX       Five Prime Thera
Last Price Today's Change   Day's Range   Trading Volume
16.45   +0.33 (2.05%)  15.82 - 16.56  465,100


Avg Volume (4 weeks):626,911
4 Weeks Range:15.82 - 22.75
4 Weeks Price Volatility (%):
52 Weeks Range:15.82 - 48.87
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

  Be the first to like this.


2315  5353  800  86 

Top 10 Active Counters
 SPY 270.49-3.71 
 NVCN 0.124-0.01 
 FB 172.56-12.53 
 QQQ 167.10-3.92 
 MU 60.14-0.44 
 TVIX 8.09+1.21 
 GE 14.07-0.24 
 EEM 48.68-0.53 
 F 11.01-0.14 
 UVXY 16.40+2.04 
Partners & Brokers